Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025)
Innate Pharma (IPHA) reported Income from Continuing Operations of 57244167.92 for Q4 2025, down 8.28% on a YoY basis from 62415096.26 in Q4 2024, and down 136.93% quarter-over-quarter from 24160547.58 in Q2 2025.
Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Innate Pharma has reported Income from Continuing Operations for 7 years, with the latest figure at 57244167.92 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 8.28% year-over-year to 57244167.92; the trailing twelve-month figure through Dec 2025 stood at 160937242.48 (down 92.27% YoY), and the FY2025 full-year result was 57244167.92, down 8.28% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 57244167.92, down from 24160547.58 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7525492.21 in Q2 2021, with the low at 57244167.92 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 23296178.79 across 5 years, with a median of 24160547.58 in 2025.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations jumped 166.11% — and 2023, when it sank 13670.83%.
- Innate Pharma's Income from Continuing Operations stood at 52025510.92 in 2021, then jumped by 99.89% to 59145.78 in 2022, then slumped by 13670.83% to 8144865.11 in 2023, then tumbled by 549.05% to 52864483.04 in 2024, then decreased by 8.28% to 57244167.92 in 2025.
- The last three Income from Continuing Operations figures came in at 57244167.92 (Q4 2025), 24160547.58 (Q2 2025), and 52864483.04 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 3.98 Mn |
| Dec 31, 2022 | -59,145.78 |
| Dec 31, 2021 | -52.03 Mn |
| Jun 30, 2021 | 7.53 Mn |
| Dec 31, 2020 | -988,408.29 |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |